FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2786993313> ?p ?o ?g. }

• W2786993313 endingPage "13" @default.
• W2786993313 startingPage "1" @default.
• W2786993313 abstract "Immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) are a standard of care for advanced melanoma. Novel toxicities comprise immune-related adverse events (irAE). With increasing use, irAE require recognition, practical management strategies, and multidisciplinary care. We retrospectively evaluated the incidence, kinetics, and management of irAE in 41 patients receiving anti-PD-1 antibody therapy (pembrolizumab) for advanced melanoma. 63% received prior anti-CTLA-4 antibody therapy (ipilimumab). IrAE occurred in 54%, most commonly dermatological (24%), rheumatological (22%), and thyroid dysfunction (12%). Thyroiditis was characterised by a brief asymptomatic hyperthyroid phase followed by a symptomatic hypothyroid phase requiring thyroxine replacement. Transplant rejection doses of methylprednisolone were necessary to manage refractory hepatotoxicity. A bullous pemphigoid-like skin reaction with refractory pruritus responded to corticosteroids and neuropathic analgesia. Disabling grade 3-4 oligoarthritis required sulfasalazine therapy in combination with steroids. The median interval between the last dose of anti-CTLA-4 antibody and the first dose of anti-PD-1 therapy was 2.0 months (range: 0.4 to 22.4). Toxicities may occur late; this requires vigilance and multidisciplinary management which may allow effective anticancer therapy to continue. Management algorithms for thyroiditis, hypophysitis, arthralgia/arthritis, colitis, steroid-refractory hepatitis, and skin toxicity are discussed." @default.
• W2786993313 created "2018-02-23" @default.
• W2786993313 creator A5003158768 @default.
• W2786993313 creator A5006685082 @default.
• W2786993313 creator A5008627423 @default.
• W2786993313 creator A5035129461 @default.
• W2786993313 creator A5038842219 @default.
• W2786993313 creator A5052303956 @default.
• W2786993313 creator A5055983682 @default.
• W2786993313 creator A5058844905 @default.
• W2786993313 creator A5087214355 @default.
• W2786993313 date "2018-01-01" @default.
• W2786993313 modified "2023-10-08" @default.
• W2786993313 title "Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management" @default.
• W2786993313 cites W1526068104 @default.
• W2786993313 cites W1605630196 @default.
• W2786993313 cites W2020727013 @default.
• W2786993313 cites W2033009850 @default.
• W2786993313 cites W2043115278 @default.
• W2786993313 cites W2061904336 @default.
• W2786993313 cites W2073456560 @default.
• W2786993313 cites W2097995306 @default.
• W2786993313 cites W2104347254 @default.
• W2786993313 cites W2109653150 @default.
• W2786993313 cites W2118982164 @default.
• W2786993313 cites W2125616358 @default.
• W2786993313 cites W2133075384 @default.
• W2786993313 cites W2151188864 @default.
• W2786993313 cites W2152897456 @default.
• W2786993313 cites W2152980179 @default.
• W2786993313 cites W2153942285 @default.
• W2786993313 cites W2164004052 @default.
• W2786993313 cites W2166662937 @default.
• W2786993313 cites W2177405394 @default.
• W2786993313 cites W2222086386 @default.
• W2786993313 cites W2234757355 @default.
• W2786993313 cites W2335934974 @default.
• W2786993313 cites W2344626562 @default.
• W2786993313 cites W2436457051 @default.
• W2786993313 cites W2547133566 @default.
• W2786993313 cites W2551387057 @default.
• W2786993313 cites W2560367415 @default.
• W2786993313 cites W2572174216 @default.
• W2786993313 cites W2597772749 @default.
• W2786993313 cites W2735117693 @default.
• W2786993313 cites W2736166064 @default.
• W2786993313 cites W2747107882 @default.
• W2786993313 cites W2753432434 @default.
• W2786993313 doi "https://doi.org/10.1155/2018/9602540" @default.
• W2786993313 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5828308" @default.
• W2786993313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29610684" @default.
• W2786993313 hasPublicationYear "2018" @default.
• W2786993313 type Work @default.
• W2786993313 sameAs 2786993313 @default.
• W2786993313 citedByCount "19" @default.
• W2786993313 countsByYear W27869933132018 @default.
• W2786993313 countsByYear W27869933132019 @default.
• W2786993313 countsByYear W27869933132020 @default.
• W2786993313 countsByYear W27869933132021 @default.
• W2786993313 countsByYear W27869933132022 @default.
• W2786993313 crossrefType "journal-article" @default.
• W2786993313 hasAuthorship W2786993313A5003158768 @default.
• W2786993313 hasAuthorship W2786993313A5006685082 @default.
• W2786993313 hasAuthorship W2786993313A5008627423 @default.
• W2786993313 hasAuthorship W2786993313A5035129461 @default.
• W2786993313 hasAuthorship W2786993313A5038842219 @default.
• W2786993313 hasAuthorship W2786993313A5052303956 @default.
• W2786993313 hasAuthorship W2786993313A5055983682 @default.
• W2786993313 hasAuthorship W2786993313A5058844905 @default.
• W2786993313 hasAuthorship W2786993313A5087214355 @default.
• W2786993313 hasBestOaLocation W27869933131 @default.
• W2786993313 hasConcept C121608353 @default.
• W2786993313 hasConcept C126322002 @default.
• W2786993313 hasConcept C16005928 @default.
• W2786993313 hasConcept C197934379 @default.
• W2786993313 hasConcept C2777077863 @default.
• W2786993313 hasConcept C2777658017 @default.
• W2786993313 hasConcept C2777701055 @default.
• W2786993313 hasConcept C2778696486 @default.
• W2786993313 hasConcept C2778917330 @default.
• W2786993313 hasConcept C2780030458 @default.
• W2786993313 hasConcept C2780057760 @default.
• W2786993313 hasConcept C2780194577 @default.
• W2786993313 hasConcept C2780366729 @default.
• W2786993313 hasConcept C2781433595 @default.
• W2786993313 hasConcept C526584372 @default.
• W2786993313 hasConcept C71315377 @default.
• W2786993313 hasConcept C71924100 @default.
• W2786993313 hasConcept C90924648 @default.
• W2786993313 hasConceptScore W2786993313C121608353 @default.
• W2786993313 hasConceptScore W2786993313C126322002 @default.
• W2786993313 hasConceptScore W2786993313C16005928 @default.
• W2786993313 hasConceptScore W2786993313C197934379 @default.
• W2786993313 hasConceptScore W2786993313C2777077863 @default.
• W2786993313 hasConceptScore W2786993313C2777658017 @default.
• W2786993313 hasConceptScore W2786993313C2777701055 @default.
• W2786993313 hasConceptScore W2786993313C2778696486 @default.
• W2786993313 hasConceptScore W2786993313C2778917330 @default.

• next